Mouse (CD1, Rag2-/-, hemophilia A models) and cynomolgus/rhesus monkey; all males
“As the clinical schedule foresees one unique injection of BMN 270, all non-clinical studies supporting the safety of BMN 270 are single-dose toxicity studies conducted by the IV route, in male animals, in different animal species (Rag2-/- mice, Rag2-/- x FVIII-/- mice, CD1 mice, monkeys), which is acceptable.”
No surrogate; clinical vector tested, though one pivotal GLP mouse study used early process B material
“The first GLP toxicity study (Study BMN 270-14-030) conducted in CD1 normal male mice used a batch of BMN 270 produced according to process B, which far diverges from process D and D’ used in phase III clinical trials and commercial process.”